NCT00290771View on ClinicalTrials.gov

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

PHASE2TerminatedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Recurrent Glioblastoma Multiforme (GBM)
Interventions
DRUG

Imatinib tablets

Imatinib was supplied as 100 and 400 mg tablets by Novartis.

DRUG

Hydroxyurea capsules

Hydroxyurea was supplied locally as 500 mg capsules.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00290771 - Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter